NEW YORK / Dec 11, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.
Details of the presentations are as follows:
Title: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorder
Format: Poster
Presenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed
Title: Rapid and durable response to a single dose of MM120 (lysergide) in generalized anxiety disorder: A dose-optimization study
Format: Poster
Presenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed
Posters are available on MindMed’s Company website.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
This press release is not sanctioned by ACNP.
| Last Trade: | US$5.60 |
| Daily Change: | 0.05 0.90 |
| Daily Volume: | 634,981 |
| Market Cap: | US$410.650M |
April 15, 2025 March 06, 2025 February 04, 2025 January 30, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
